Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia

Rainer Storb, H. Joachim Deeg, John Whitehead, +18

New England Journal of Medicine

Analysis of 462 Transplantations from Unrelated Donors Facilitated by the National Marrow Donor Program

Nancy A. Kernan, Glenn E. Bartsch, Robert C. Ash, +14

New England Journal of Medicine

Marrow Transplantation from Related Donors Other Than HLA-Identical Siblings

Patrick G. Beatty, Reginald A. Clift, Eric Mickelson, +9

New England Journal of Medicine

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, +617

The Lancet Oncology

5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials +8

Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma

Claudio Anasetti, Patrick G. Beatty, R Storb, +5

Human Immunology

Hla IncompatibilityGraft-versus-host DiseaseTransplantationMarrow TransplantationImmunology +9

MARROW TRANSPLANTATION FROM HLA-MATCHED UNRELATED DONORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES

Patrick G. Beatty, JOHN A. HANSEN, Gary Longton, +17

Transplantation

Unrelated Volunteer DonorsUnrelated DonorsTransplantationOncologyMarrow Transplantation +11

IMPACT OF RACIAL GENETIC POLYMORPHISM ON THE PROBABILITY OF FINDING AN HLA-MATCHED DONOR

Patrick G. Beatty, MOTOMO MORI, Edgar L. Milford

Transplantation

HlaHistocompatibilityEthnicityGenetic TestingGenetics +20

HLA GENE AND HAPLOTYPE FREQUENCIES IN THE NORTH AMERICAN POPULATION

Motomi Mori, Patrick G. Beatty, Michael C. Graves, +2

Transplantation

Prospective Trial of Chemotherapy and Donor Leukocyte Infusions for Relapse of Advanced Myeloid Malignancies After Allogeneic Stem-Cell Transplantation

John E. Levine, Thomas Braun, Samuel L. Penza, +12

Journal of Clinical Oncology

Cell TherapyImmunologyProspective TrialImmunotherapyMyeloid Neoplasia +19

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada, +203

The Lancet Oncology

Lymphoid NeoplasiaEnd-of-induction Pet ResponseMedicinePrognostic ValueFollicular Lymphoma +5